NextPharma to sell logistics arm to Cencora as part of plan to position NextPharma as Europe’s leading pure-play CDMO
13th October 2025 – NextPharma (“The Company”), a leading European pharmaceutical contract development and manufacturing organisation (“CDMO”), has entered into an agreement with Cencora, Inc. (“Cencora”), a global pharmaceutical solutions organisation, to sell NextPharma’s healthcare logistics services business, NextPharma Logistics GmbH (“NextPharma Logistics”).
The transaction is expected to complete in Q4 2025, subject to customary regulatory approvals. Terms of the transaction are not being disclosed.
The divestment forms part of NextPharma’s strategic focus on strengthening its position as a leading European CDMO, dedicated to delivering the highest quality products and services to its customers. As part of this plan, the NextPharma Logistics business - which provides pre-wholesaling and logistics services for a range of pharmaceutical and animal health clients from facilities in Germany, Austria, and Switzerland - has been identified as non-core to the Company’s long-term strategy, which is centred on commercial manufacturing and product development. With approximately 230 employees, NextPharma Logistics has built a strong reputation in its field.
Christian Pieper, Managing Director of NextPharma Logistics, comments: “We are very proud of the development and expansion of our business under NextPharma, and we are excited by the opportunities of further developing and growing the business with the Cencora team, leveraging their global expertise, resources, and network to drive continued success.”
Peter Burema, CEO of NextPharma, comments: “We are extremely pleased that we have found an attractive partner to whom to divest our healthcare logistics services business, which is non-core and has no overlap with our core commercial manufacturing and product development business. We know the business will continue to flourish and wish Christian and the whole NextPharma Logistics team every success in their new chapter. For NextPharma Logistics’ people and customers it remains business as usual until the transaction is completed.”
As part of its CDMO strategy, NextPharma has continued to make significant new investments across the business as part of its commitment to provide customers with the highest quality products and services. This has recently included the expansion of its centre of excellence in Limay, France, specialised in the development and manufacture of liquid dosage forms. It is also devoting significant investment to the expansion of its facility in Tampere, Finland, specialised in the development andmanufacture of ophthalmic products in a variety of dosage forms.
About NextPharma
NextPharma is a leading European pharmaceutical contract development and manufacturing organisation (“CDMO”) with a current footprint spanning ten sites, five in Germany, two in France and one in each of Finland, Norway and Scotland. NextPharma supplies products globally, with all of its ten sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets,chewable tablets, capsules, granules, powders, pellets, gels, creams, liquid-filled capsules, softgels, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes. NextPharma’s expertise and centres of excellence enable it to provide a unique service offering in certain very specific specialised areas such as hormonal solids and semi-solids, cephalosporins, penicillins, modified release products, lipid-based formulations (including hormonal and high potent products), as well as paediatric medicinal products. For more information, please visit www.nextpharma.com.